Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
复制标题
DOI：
10.1093/eurheartj/ehv186
复制
发表时间：
2015-08-07
影响因子：
39.3
通讯作者：
Solomon, Scott D.
中科院分区：
文献类型：
--
作者：
Desai, Akshay S.;McMurray, John J. V.;Solomon, Scott D.
目的：在ARNI与血管紧张素转换酶抑制剂确定心力衰竭患者总体死亡率和死亡率影响的前瞻性比较（PARADIGM-HF）试验中，与依那普利相比，血管紧张素受体脑啡肽酶抑制剂（ARNI）LCZ 696降低慢性心力衰竭患者的心血管死亡率和全因死亡率。为了更全面地了解这种死亡率获益的组成部分，我们研究了LCZ 696对死亡模式的影响。方法和结果PARADIGM-HF是一项前瞻性、双盲、随机试验，纳入8399例慢性心力衰竭、纽约心脏协会II-IV级症状和左心室射血分数
Aims The angiotensin-receptor-neprilysin inhibitor (ARNI) LCZ696 reduced cardiovascular deaths and all-cause mortality compared with enalapril in patients with chronic heart failure in the prospective comparison of ARNI with an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. To more completely understand the components of this mortality benefit, we examined the effect of LCZ696 on mode of death.Methods and results PARADIGM-HF was a prospective, double-blind, randomized trial in 8399 patients with chronic heart failure, New York Heart Association Class II-IV symptoms, and left ventricular ejection fraction